Erica Mayer (@elmayermd) ranks #14 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: EVERA. CMS Open Payments lists $85,449 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Breast Cancer: US #14, Global #29 · 14 physicians engaged
- Presented at ESMO 2026 in 2026
- CMS Open Payments lists $85,449 in 2025 general payments.
This Month
What Erica Mayer has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Erica Mayer
Physicians who reposted Erica Mayer’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #14 | #29 | 14 | 22 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Erica Mayer presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · PosterExpert consensus on the management of ribociclib-associated liver-related adverse events in HR+/HER2- breast cancerSource: @DFCI_BreastOnc on X ↗
What Colleagues Are Saying About Erica Mayer
2026 posts by fellow physicians that mention @elmayermd, quoted word for word.
evERA, by @elmayermd, @stolaney1 et al, is now published in NEJM. Giredestrant outperformed SoC ET when combined with everolimus in HR+/HER2- MBC, particularly in ESR1 mutant disease. Looking forward to having this highly active combo available in clinic. https://t.co/tmEFGZGGOw https://t.co/xUx4cGRoPH
Camizestrant is now @FDA ✅ for HR+ metastatic #breastcancer with emersion of mESR1 prior to progression. Here we 🗣️ this trial, findings, & clinical implications w/ @elmayermd Full 🗣️ ⭐️ https://t.co/UShrrDGIlz ⭐️ “Oncology Brothers” podcast @OncUpdates @OncoAlert #bcsm https://t.co/mWIKlyLT77
A huge congratulations to @elmayermd and team on the publication of evERA in @NEJM! Hoping we get approval for giredestrant + everolimus in the near future -- this would be wonderful for our patients with HR+ MBC! https://t.co/83YHPb85hi @DFCI_BreastOnc
Today at 4 PM !! @stolaney1 @elmayermd @nlinmd and others join us for a discussion of highlights from ESMO-breast and preview of key ASCO discussions. Program is live, unrehearsed, and free to join but registration required. See link below. https://t.co/I8SzzhsoVH
Trials Erica Mayer Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| EVERA | 1 | #5 of 30 | Sep 30, 2026 |
Erica Mayer on EVERA
Excited for publication of results of the evERA breast cancer trial, demonstrating the efficacy of the oral SERD combination of giredestrant and everolimus in advanced ER+ breast cancer. Wonderful news for breast cancer patients and clinicians! https://t.co/WqXlsAHygb
Industry Payments
CMS Open Payments · 2025 general payments
$85,449 across 52 payments